We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • News
  • Blogs
  • Image IQ
  • Podcasts
  • Topics
  • Conferences
  • About

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • News
  • Blogs
  • Image IQ
  • Podcasts
  • Topics
  • Conferences
  • About

SUBSCRIBE: eNewsletter

Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

  • Bryant Furlow
Jul 6, 2017
  • Leukemia & Lymphoma, Hematologic Cancer Targets

Nivolumab was associated with durable objective response rates (ORRs) in adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation (ASCT), according to an extended follow-up analysis from the phase II CheckMate-205 clinical trial. The findings were presented at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland.

“Treatment options are limited for patients with classical Hodgkin lymphoma after ASCT has failed, which is why the high objective response rates shown across cohorts of the CheckMate-205 study are encouraging,” said lead study author Michelle Fanale, MD, of the University of Texas MD Anderson Cancer Center in Houston. “The results are particularly welcome news, as patients experienced responses regardless of brentuximab vedotin treatment history or the depth of their Hodgkin lymphoma’s response to brentuximab vedotin.”

“Notably, with extended follow-up, both CRs [complete responses] and PRs [partial responses] remain durable,” they reported.

A total of 243 patients participated in the study in three cohorts; they received nivolumab 3 mg/kg every 2 weeks until tumor progression or unacceptable toxicity. Sixty-three patients were brentuximab vedotin–naïve (Cohort A). Cohort B included 80 patients administered brentuximab vedotin after ASCT. Cohort C included 100 patients administered brentuximab vedotin before ASCT, after ASCT, or both (n = 33, 58, and 9, respectively). In December 2016, at a median follow-up of 19, 23, and 16 months for the three cohorts, 40% of patients remained on treatment overall, the authors reported.

ORRs were 65% in brentuximab vedotin–naïve patients (Cohort A), compared with 68% in patients who received brentuximab vedotin after ASCT (Cohort B), and 73% in Cohort C. CR rates were 29%, 13%, and 12%, respectively.

Duration of response was 20 months, 16 months, and 15 months among patients in Cohorts A, B, and C.

“For patients with CR, duration of response was 20 months in brentuximab vedotin–naïve patients (Cohort A) and ≥ 15 months in brentuximab vedotin–treated patients (Cohorts B and C),” the authors reported.

Progression-free survival for cohorts A, B, and C were similar: 18.3 (95% CI, 11.1-22.4), 14.7 (95% CI, 10.5-19.6) and 11.9 (95% CI, 11.1-18.4). Overall survival was not yet calculable.

“The most common drug-related adverse events were fatigue (23%), diarrhea (15%), and infusion reactions (14%),” they reported.

Related Articles

  • MMG49 Identified as a New Target in Multiple Myeloma
  • Combination Therapy Proposed for Multiple Myeloma and Mantle Cell Lymphoma
  • New Guidelines Proposed for Preventing and Treating CAR T-Cell Side Effects
  • Link Between Fanconi Anemia Genetic Mutations and Cancer Risk
  • New Study Offers Insights into Tyrosine Kinase Inhibition in AML Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
There are currently no available Sponsored Topics
There is currently no available content. Please check back soon.
Connect with Us
  • Twitter
  • Facebook
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.